2 Vaccine Global Congress

De 7 de Dezembro de 2008 até 9 de Dezembro de 2008

Boston, US

Público alvo: Médico Veterinário, Alunos de graduação, Alunos de pós-graduação

Sunday December 7, 2008
Plenary session 1: Setting the Scene
11.00
Welcome
Ray Spier, University of Surrey, UK
11.10
Future of vaccine discovery
Adel Mahmoud, Princeton University, USA
11.45
Development of self-administrative vaccine by MucoRiceTM System
Hiroshi Kiyono, University of Tokyo, Japan
12.10
Pathogenic epitopes, heterologous immunity, and vaccine design
Raymond Welsh, University of Massachusetts Medical School, USA
12.35
Duration of immunity following vaccination: How long it can last and how we can make it better
Mark K. Slifka, Oregon Health & Science University, USA
13.00
Lunch
Plenary session 2: Major Infectious Disease Targets
14.00
The reiterative discovery process – HIV vaccine prevention research moving forward post The STEP Trial
Elizabeth Adams, NIAID, USA
14.10
Developing HIV vaccines with protective antibody responses
Shan Lu, University of Massachusetts Medical School, USA
14.35
New vectored vaccines for malaria
Adrian Hill, The Jenner Institute, UK
15.00
TB vaccine development
Michael J. Brennan, Aeras Global TB Vaccine Foundation, USA
15.25
Coffee and Exhibition Viewing
15.30
Poster Session
Human Vaccines Infectious Disease
Human Vaccines Non Infectious Disease
Plenary session 3: Non-traditional Vaccines
16.00
Of mice and men (and dogs): Clinical development of Xenogeneic DNA vaccines for cancer
Polly Gregor, Memorial Sloan-Kettering Cancer Center, USA
16.25
Computer-driven vaccine design: from concept to reality
Annie de Groot, EpiVax Inc., USA
16.50
Acne vaccines targeting P. acnes virulent factors
Eric Huang, University of California, USA
17.00
Development of AAV as potent B-cell vaccine directed against human IgE for the treatment of severe allergic asthma
Marcus Hoerer, MediGene AG, Germany
17.10
Th-1 Immunity is regulated by dendritic cell comparison of MHC Class I and Class II antigens: implications for successful immunotherapy of neoplasia
William Decker, University of Texas MD Anderson Cancer Centre, USA
17.20
Preclinical studies on the generation of conjugated vaccines for addictive drugs
Philippe Leff, National Institute of Psychiatry, Mexico
17.30 – 19.30
Opening reception - Poster & Exhibit hall
17.30 – 18.30
Poster Session
Human Vaccines Infectious Disease
Human Vaccines Non Infectious Disease
Monday December 8, 2008
Plenary session 4: Adjuvants
8.30
Innate immune pattern recognition receptors and vaccine adjuvants
Kate A. Fitzgerald, University of Massachusetts Medical School, USA
8.55
Use of CpG Oligonucleotides as a vaccine adjuvant
Dennis Klinman, NCI-Frederick, USA
9.20
An MF-59 adjuvanted H5N1 clade 1 pre-pandemic vaccine confers cross-reactive antibodies to a clade 2 H5N1 virus strain
Angelika Banzhoff, Novartis, Germany
9.30
AS03-adjuvanted prepandemic influenza vaccine: high immunogenicity in the elderly
Stephane Heijmans, ResearchLink, Belgium
9.40
Aluminum hydroxide adjuvants activate the immune system through the Nalp3 Inflammasome
Stephanie Eisenbarth, Yale School of Medicine, USA
9.50
The non toxic B subunit of Shiga Toxin coupled to various antigens elicits mucosal humoral and cellular immune responses
Eric Tartour, Hopital Européen Georges Pompidou, France
10.00
Adjuvanting a DNA vaccine With a TLR9 Ligand Plus Flt3 Ligand Results in Enhanced Cellular Immunity Against the Simian Immunodeficiency Virus
Marcin Kwissa, Emory Vaccine Center, USA
10.10
Activation of MyD88 dependent TLR 7/8 pathway leads to cell mediated responses by levamisole as a potent adjuvant for therapeutic vaccination against HBV infection
Bin Wang, China Agricultural University, China
10.20
DNA vaccine prime improved the antigen-specific B cell memory and longevity of B cell responses against V antigen of Yersinia pestis in mice
Wei Li, University of Massachusetts Medical School, USA
10.30 - 11.00
Exhibit hall and Coffee
10.30 - 11.00
Poster Session
Adjuvants
Delivery Systems
Late Breaker
Production & Other
Plenary session 5: Delivery systems
11.00
Vaccination into or onto the skin: advantages, accomplishments, actualizations, and adumbrations of the cutaneous route
Bruce G. Weniger, Centers for Disease Control and Prevention, USA
11.25
Novel adenovirus vector-based vaccines for HIV-1
Dan Barouch, Harvard Medical School, USA
11.50
Development of sendai virus-based vaccines to prevent pediatric respiratory virus infections
Julia Hurwitz, St. Jude Children's Research Hospital USA
12.00
Field efficacy results from a field trial show a patch containing heat labile enterotoxin from Escherichia coli (LT) protects against travelers’ diarrhea
Sarah Frech, Intercell USA Inc
12.10
West Nile virus DNA vaccine producing single round infectious particles protects mice from lethal encephalitis and induce virus-neutralising antibodies in horses
David Chang, University of Queensland, Australia
12.20
Electroporation mediated DNA immunization: Comparative performance versus classical vaccine approaches and transition to human clinical testing
Brian Livinston, Ichor Medical Systems, USA
12.30 - 2.15
Lunch
12.30 - 13.30
Poster Session
Adjuvants
Delivery Systems
Late Breaker
Production
Other
Plenary Session 6
14.15 – 15.15
Influenza Immunization of Health Care Workers: A Patient Safety Imperative
Gregory A. Poland, Mayo Vaccine Research Group, USA
ISV selected abstract presentation
15.15
Improved immunogenicity of adenoviral vaccines: Impact of tethering the vaccine antigen to MHC-class II associated invariant chain
Allen Thomsen, University of Copenhagen, Denmark
15.25
Yersinia pestis live vaccine with improved characteristics
Valentina Feodorova, Saratov State University, Russia
15.35
Development of the DNA plasmid based genetic vaccine vectors, which use segregation/partitioning functions of the episomally replicating DNA viruses
Mart Ustav, FIT Biotech Oy Eesti AS, Estonia
15.45
Development of recombinant G protein-based vaccine for Chandipura virus
Vidya Arankalle, National Institute for Virology, India
15.55 – 16.30
Exhibit hall and Coffee
16.00 – 16.30
Poster Session
Adjuvants, Delivery Systems
Late Breaker
Production
Other
Breakout session 1: Vaccine production and clinical use
16.30
Stability of vaccines
Rich Costantino, USA
16.55
Vaccine stability monitoring using the LifeTrack® electronic stability monitor
Stephan Zweig, Clinisense Corporation, USA
17.05
System and process for large-scale DNA Vaccine Production by PCR
Derek Gregg, Vandalia Research, USA
17.15
Development of an Universal Influenza A vaccine using an innovative plant virus based platform
Denis Leclerc, Laval University, Canada
17.25
Phase 1, Double-Blinded, Placebo-Controlled, Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Hana El Sahly, Baylor College of Medicine, USA
17.35
Mother and daughter preferences and willingness to pay for HPV vaccination
Derek Brown, RTI International Research, USA
17.45
Maternal Immunization: an underutilized strategy to protect both mothers and infants
Mark Steinhoff, Cincinnati Childrens Hospital Medical Center, USA
17.55 - 18.05
Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008
Cathy Panozzo, Center for Disease Control and Prevention, USA
Breakout session 2: Late Breakers Abstracts - 1
16.30
Modeling of a highly conserved influenza HA2 epitope for vaccination and evaluation in the mouse challenge model
Jan ter Muelen, Merck & Co, USA
16.40
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein confers long time protection against RSV infection in cotton rats
Myra Widjojoatmodjo, Netherlands Vaccine Institute, The Netherlands
16.50
RepliVax®: new replication-defective flavivirus vaccines and vectors for non-flavivirus immunogens
Maryann Giel-Moloney, Acambis, USA
17.00
Non-replicating adenovirus-vectored avian influenza vaccine as a rapid-response tool for mitigating a pandemic
De-Chu Tang, Vaxin Inc, USA
17.10
Chimeric Alphavirus Vaccines for Western Equine Encephalitis
Eryu Wang, University of Texa, USA
17.20
Antigens Recognized by Cytotoxic and Helper T Lymphocytes with Vaccine Potential for Cancer Patients
Dorothee Herlyn, The Wistar Institute, USA
17.30
A genetically attenuated feline coronavirus vaccine: protection against feline infectious peritonitis (FIP) by cellular rather than by virus-neutralizing immunity
Peter Rottier, Utrecht Universtiy, The Netherlands
17.40
Fusion inactivation of H5N1 whole inactivated virus (WIV) vaccine does not compromise its superior immunogenicity
Aalzen De Haan, The Netherlands
17.50 - 6.00
Down-Regulation of Influenza Viral Vaccination by CD4+25hi T-Regulatory Cells
Cristina Nazarov, Uniformed Services University, USA
19.00
Coaches depart for Conference dinner from outside of the hotel lobby
Tuesday December 9, 2008
Plenary session 7: Novel Bacterial Vaccines
8.30
Vaccines: an health insurance of the 21st century
Rino Rappuoli, Novartis Vaccines and Diagnostics, Italy
8.55
Development of a novel Staphylococcus aureus vaccine based on a conserved protein antigen
John W. Shiver, Merck and Co Inc., USA
9.20
Pneumococcal conjugate vaccines: What do we know and what do we need?
Jennifer Schranz, Wyeth, USA
9.45
Development of a full coverage pneumococcal vaccine comprising highly conserved proteins with a crucial function in the bacterial life cycle
Carmen Giefing, Intercell AG, Austria
9.55
A Phase III head-to-head comparison of a novel quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, with the licensed meningococcal ACWY conjugate vaccine, Menactra®, in healthy subjects 11-55 years of age
Peter Dull, Novartis, USA
10.05
Vaxign: a web-based vaccine target design program for reverse vaccinology
Yongqun He, University of Michigan, USA
10:15
Safety & immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given with routine vaccines in healthy infants
D. M. Kieninger, Wyeth, USA
10.25 – 11.00
Exhibit hall and Coffee
10.30 - 11.00
Poster session
Vetinary Vaccines
Immunology/Animal Models
Plenary session 8: Emerging Infectious Disease & Biodefense
11.00
Characterization of type-specific and dengue complex antigenic sites on the envelope protein domain III of dengue viruses
Alan Barrett, University of Texas Medical Branch, USA
11.25
The ferret and human models for influenza vaccine evaluation
John S. Oxford, Retroscreen Virology Ltd, UK
11.50
Toward the development of a SARS vaccine
Jeffrey Ulmer, Novartis, USA
12.00
Induction of Longitudinal Cross-Clade Anti-H5N1 Immunity and Protection by Homologous and Heterologous Prime-Boost Immunization Regimes with Whole Virus H5N1 Influenza Candidate vaccines
Nicolas Sabarth, Baxter Innovations GmbH, Austria
12.10
Genetic and clinical evaluation of MP-12: A live attenuated vaccine for Rift Valley fever virus (RVFV)
George Bettinger, University of Texas Medical Branch, USA
12.20
A ML29 Reassortant lassa fever vaccine is safe and induces broad cell-mediated protective immune responses in experimental animals
Igor Lukashevich, Institute of Human Virology, USA
12.30
Phase 1, Double-Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Reactogenicity of Francisella tularensis Live Vaccine Strain (LVS) Administered by the Scarification or Subcutaneous Route
Hana El Sahly, Baylor College of Medicine, USA
Breakout session 3: Late Breaker Abstracts - 2
11.00
Strategies for achieving efficient implementation of an expanded ACIP recommendation for influenza vaccination of school-aged children
Harry Hull, HF Hull & Associates, USA
11.10
The value of information when considering introduction of a new vaccine in the immunisation schedule: A conjoint analysis conducted in Europe
Benoit Dervaux, CRESGE, France
11.20
Rational design and standardized evaluation of novel genetic vaccines
David Klatzmann, UMR 7087 UPMC-CNRS, France
11.30
Prime-boost vaccination with DNA-transduced autologous lymphocytes protects against fully virulent homologous challenge in the feline immunodeficiency virus AIDS model
Mario Pistello, University of Pisa, Italy
11.40
Exploit of nanogel as a novel carrier of mucosal vaccine: Nanogel mucosal vaccine effectively induces protective immunity against botulinum toxin
Tomonori Nochi, University of Tokyo, Japan
11.50
Vaccination of broiler chickens with dry powder vaccines as an alternative for liquid spray and aerosol vaccination
Wil Landman, Animal Health Service, The Netherlands
12.00
HIV-1 resistance towards CADA-induced CD4 receptor-targeted inhibition is associated with increased sensitivity to neutralizing antibodies
Dominique Schols, Rega Institute for Medical Research, Belgium
12.10
Sequential vaccination with heterologous HIV Env immunogens stimulates broad neutralization antibodies against different HIV clade derived primary isolates
Jianqing Xu, Shanghai Public Health Clinical Center, Fudan University, China
12.20
Challenges and potential solutions to innovative vaccine development in developing countries
Julie Milstien, University of Maryland School of Medicine, USA
12.30
Exhibit hall and Lunch
12.45-13.15
Poster Session
Veterinary Vaccines
Immunology/Animal Models
Plenary 9: Vaccine Policy and Public Health Issues
14.00
Current & future U.S. Government funding for vaccine R&D and acquisition
Dack Dalrymple, Dalrymple & Associates, LLC, USA
14.25
Vaccine safety
Bob Chen, Centers for Disease Control and Prevention, USA
14.50
Implementing vaccination programs in developing countries
Jon Andrus, Pan American Health Organization, USA
15.15
Improving on Mother Nature's Immunogenicity
Peter Nara, Biological Mimetics Inc, USA
15.40 - 16.05
Dealing with ethical issues in the area of vaccines and vaccination
Ray Spier
Closing Summary
Ray Spier and Shan Lu

Outras formas de contato: Marie-Claire Morley Vaccine Secretariat Tel: +44 (0) 7903 406176 Fax: +44 (0) 208 181 6697 Email: [email protected]

Saiba mais sobre o evento

Medicina veterinária Medicina humana